Archive · 23 Sep 2026
India Leads Emerging Markets in Agritech Funding, Report Says
A report studied agritech investments in 17 emerging markets.
It found that India received the most money, about $2.1 billion.
The total amount tracked across all the markets was $4.39 billion.
The report says Indian farm and food companies have several ways to grow and attract investors.
These include being bought by larger companies, receiving private-equity investment or becoming publicly listed.
Future investments may focus on biology, farm supplies, machines, drones and robots, not just software.
The report also sees opportunities in food brands, processing and consumer products.
However, agritech investment has recovered more slowly than the wider startup market because farming businesses can take longer to sell and need expensive physical infrastructure.
The report warns that its figures cover only publicly disclosed deals and may underestimate total funding.
India received $2.1 billion of the $4.39 billion in agritech funding tracked across 17 emerging markets from 2023 through the third quarter of 2025.
India’s funding exceeded the combined totals reported for Brazil, Indonesia and Kenya, and 92% of Indian deals included at least one commercial investor.
The report classifies India, Brazil, Indonesia, Chile and Argentina as “Commercial Front Runners” with strong conditions for agrifood investment.
South Asia was identified as the only region studied with diverse, repeatable exit routes, including acquisitions, private-equity deals and public listings.
Future Indian opportunities may increasingly involve agricultural biology, inputs, AI-enabled hardware, drones, robotics, finance, infrastructure and consumer food businesses.
- Who
- AgBase, Briter and ISF Advisors produced the AgTech Investment in Emerging Markets 2025 report; Mark Kahn of Omnivore was quoted in a statement about it.
- What
- The report found that India led 17 emerging markets in tracked agritech funding, receiving $2.1 billion.
- When
- The funding period ran from January 2023 through the third quarter of 2025; the report was published on September 22, 2026.
- Where
- The study covered 17 emerging markets, with India and South Asia receiving particular attention.
- Why
- The report attributes India’s investment appeal to its agricultural scale, digital infrastructure, entrepreneurial talent, domestic capital, exit routes and supportive government policy.
India’s Investment Strengths
Investment Cautions and Limits
Market attractiveness
India’s Investment Strengths
The report says India combines agricultural scale, digital infrastructure, entrepreneurial talent, domestic capital, multiple exit routes and supportive policy.
Investment Cautions and Limits
Agritech recovery has been slower and more uneven than the broader startup market because of long sales cycles, climate and commodity risks, and physical-infrastructure needs.
Future opportunity
India’s Investment Strengths
The report identifies potential in agricultural biology, inputs, AI-enabled hardware, autonomous drones, robotics, finance, value-chain infrastructure and consumer food businesses.
Investment Cautions and Limits
The report indicates that opportunities vary by market: Latin America currently has stronger commercial routes to scale and exit for biological products, while South and Southeast Asia are still building commercial interest.
Funding figures
India’s Investment Strengths
India accounted for nearly half of the funding tracked across the 17 markets and ranked first among them.
Investment Cautions and Limits
The figures include only publicly disclosed deals, and the report estimates that total capital flows may be 15% to 25% higher.
- Funding tracked
- More than $4.39 billion
- Markets studied
- 17 emerging markets
- India’s funding
- $2.1 billion
- Study period
- January 2023 through the third quarter of 2025
- India deal participation
- 92% of deals included at least one commercial investor
- Commercial Front Runners
- India, Brazil, Indonesia, Chile and Argentina
- Data limitation
- The dataset covers publicly disclosed deals and may understate total capital flows by 15% to 25%
